Mansi Mehta, MD
Endocrinology, Diabetes & Metabolism · Albuquerque, NMNPI 1790933778
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,336 of the $14,711 with a category attached, or 70.3%. Novo Nordisk accounts for 72.9% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2020 at $5,981 and has fallen 87.9% since, to $725 in 2025. Among endocrinology, diabetes & metabolism clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $75.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$11K
- Insulet Corporation$701
- Amgen$550
- Abbott$436
- Lilly USA, LLC$337
- Vertex$333
- plus $2K from 24 others
Across 1 payment — averaging $20,911 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$21K
What the payments were for
- Consulting fees$3332%
- Speaking & faculty fees$10,33670%
- Food & beverage$3,85926%
- Education$1821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $10,723 |
| Insulet Corporation | 29 | $701 |
| Amgen(2 entities) | 28 | $550 |
| Abbott | 15 | $436 |
| Lilly USA, LLC | 19 | $337 |
| Vertex | 1 | $333 |
| Medtronic(2 entities) | 7 | $225 |
| Boehringer Ingelheim | 12 | $201 |
| Dexcom, Inc. | 9 | $181 |
| Recordati_rare_diseases_inc. | 6 | $136 |
| Xeris Pharmaceuticals, Inc. | 6 | $128 |
| AstraZeneca | 6 | $95 |
| BETA Bionics, Inc. | 4 | $74 |
| Radius Health, Inc. | 4 | $67 |
| Tandem Diabetes Care, Inc. | 3 | $53 |
| Acella Pharmaceuticals, LLC | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| AbbVie | 3 | $44 |
| Pfizer | 2 | $42 |
| Johnson & Johnson | 2 | $37 |
| UCB, Inc. | 2 | $36 |
| Neurocrine Biosciences, Inc. | 1 | $35 |
| Novartis | 2 | $34 |
| Bayer | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| RGH Enterprises LLC | 1 | $22 |
| BD | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| GSK | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$6,579
- Ozempic$3,757
- FreeStyle Lite system$150
- GUARDIAN SENSOR (3)$105
How this compares
$14,711 in reported general payments places this provider in the 90th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
See all endocrinology, diabetes & metabolism providers in New Mexico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 105 | $146,937 |
| OzempicSemaglutide | 109 | $141,173 |
| FarxigaDapagliflozin Propanediol | 106 | $128,816 |
| MounjaroTirzepatide | 97 | $116,066 |
| Tresiba Flextouch U-100Insulin Degludec | 150 | $114,072 |
| TymlosAbaloparatide | 39 | $105,225 |
| SomavertPegvisomant | 12 | $97,212 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 100 | $96,553 |
| HumatropeSomatropin | 16 | $60,059 |
| JanuviaSitagliptin Phosphate | 42 | $57,159 |
| ForteoTeriparatide | 14 | $55,470 |
| Teriparatide | 17 | $46,914 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $45,519 |
| JardianceEmpagliflozin | 26 | $44,506 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 25 | $40,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humatrope, Forteo, Humalog | $337 | $424,849370 claims |
| Novo NordiskOzempic, Levemir, Novolog | $10,723 | $156,269158 claims |
| PfizerSomavert, Genotropin | $42 | $130,73226 claims |
| AstraZenecaFarxiga | $95 | $128,816106 claims |
| Radius Health, Inc.Tymlos | $67 | $105,22539 claims |
| MerckJanuvia | $13 | $57,15942 claims |
| Boehringer IngelheimJardiance | $201 | $44,50626 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $16,3031,104 claims |
| AbbVieSynthroid | $44 | $15,865189 claims |
| Sanofi-aventis U.S. LLCAdmelog | $50 | $5,78714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
Other endocrinology, diabetes & metabolism in Albuquerque
- Robert FerraroAlbuquerque$101K
- Rina Patel TrujilloAlbuquerque$100K
- Jeremy GleesonAlbuquerque$46K
- David SchadeAlbuquerque$16K
- Matthew BouchonvilleAlbuquerque$7K
- Teodor DuroAlbuquerque$6K
- Ivan PinonAlbuquerque$5K
- Namrata JannareddyAlbuquerque$4K
- Anita Sloan-GarciaAlbuquerque$4K
- Lisa EreifejAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.